Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
Executive Summary
UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.